Pegvisomant vs Tesamorelin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Pegvisomant or Tesamorelin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Pegvisomant and Tesamorelin?
Pegvisomant is a GH receptor antagonist that suppresses IGF-1; tesamorelin is a GHRH analog that stimulates GH release - they are mechanistic opposites acting on the same axis.
Evidence Comparison
Pegvisomant: FDA approved for acromegaly, ~90% IGF-1 normalization rate. Tesamorelin: FDA approved for HIV-associated lipodystrophy, Phase 3 data showing significant trunk fat reduction (Falutz et al. 2007). Both have strong Phase 3 evidence within their approved indications.
Evidence Context Favoring Pegvisomant
Acromegaly research or any context requiring GH receptor blockade and IGF-1 reduction.
Evidence Context Favoring Tesamorelin
HIV lipodystrophy or research into visceral fat reduction via GH axis stimulation - tesamorelin is the only GHRH analog with a current FDA-approved indication.
Side-by-Side Snapshot
| Evidence grade | Pegvisomant: Level A Tesamorelin: Level A |
|---|---|
| Research status | Pegvisomant: FDA Approved Tesamorelin: FDA Approved |
| Primary category | Pegvisomant: Growth Hormone Tesamorelin: Growth Hormone |
| Cited studies | Pegvisomant: 2 Tesamorelin: 3 |